Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.
Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.
Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.
Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.
For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.
Medigus Ltd. (Nasdaq: MDGS) announced that ParaZero, in which it holds a 40% stake, received a purchase order for its patented SafeAir system from a prominent global drone manufacturer. The integration of SafeAir technology aims to enhance drone safety by autonomously deploying a parachute during malfunctions, potentially saving operators millions. ParaZero's safety system has been adopted by leading companies and is compliant with ASTM F3322-18 standards, allowing advanced drone operations. The small drone shipment market is projected to reach USD $85 billion by 2025.
Medigus Ltd. (Nasdaq: MDGS) has signed a non-binding letter of intent to execute a reverse merger with Fuel Doctor, Inc. (OTC: FDOC). This transaction will make Charging Robotics, a subsidiary of Medigus, a wholly owned part of Fuel Doctor, with Medigus acquiring 80% of Fuel Doctor's outstanding shares. Fuel Doctor is expected to have a minimum of $1 million in net cash at closing. Charging Robotics aims to enhance electric vehicle charging through an automatic wireless charging platform.
Medigus Ltd. (Nasdaq: MDGS) announced that Revoltz, in which it holds a 19.9% stake, will launch a pilot project at a new autonomous supermarket in Israel.
The project includes a purchase order for Revoltz's PORTO micro-mobility vehicle designed for last-mile delivery. With the global last-mile delivery market projected to grow from $108 billion in 2020 to over $200 billion by 2027, Medigus positions its technology for this expanding demand. The PORTO unit combines robust design and functionality, ensuring efficient delivery capabilities.
Medigus Ltd. (Nasdaq: MDGS) announced the appointment of Prof. Nancy Agmon-Levin to the scientific advisory board of Polyrizon Ltd., a company in which Medigus holds a 37.03% stake. Prof. Agmon-Levin is a noted expert in immunology and allergy, currently leading the Clinical Immunology Unit at Sheba Medical Center in Israel. This addition aims to enhance Polyrizon's capabilities in addressing autoimmune diseases and allergies. Prof. Agmon-Levin joins a board already featuring renowned experts in biomaterials and drug delivery.
Medigus Ltd. (Nasdaq: MDGS) announced that its joint venture, Revoltz, has received its first order for the PORTO micro-mobility vehicle designed for the last mile delivery market. Established in under a year, Revoltz, in which Medigus holds a 19.9% stake, aims to capitalize on the growing global last mile delivery market projected to exceed $200 billion by 2027. The PORTO unit's robust design accommodates long-range deliveries and features a significant storage capacity, enhancing operational efficiency for distributors in the logistics sector.
Medigus Ltd. (Nasdaq: MDGS) announced its 47.69% owned subsidiary, Eventer Technologies Ltd., signed contracts with Israel Gymnastics Federation and Table Tennis Association. Eventer is focused on expanding its services beyond entertainment into sports by providing a platform for virtual events and smart ticketing solutions. The collaboration aims to enhance global ticket sales and event promotion. Eventer will also supply video production and marketing services for broadcasts of the events.
Medigus (Nasdaq: MDGS) announced a partnership between its subsidiary Charging Robotics and BGN Technologies to develop a next-generation wireless charging system for electric vehicles (EVs). This innovative technology aims to address the growing need for convenient and cost-effective charging solutions, particularly as EV sales surge. The system, to be installed in public lots, will use a dedicated robot to automatically recharge EVs, operating at 12kW, which aligns with standard residential chargers. The collaboration with Ben-Gurion University will leverage advanced energy transmission research.
Medigus Ltd. (Nasdaq: MDGS) announced that ParaZero Ltd., in which it holds a 40% stake, has received Brazil's first authorization for commercial drone deliveries from ANAC. This authorization allows the DLV-1 NEO drone to operate beyond visual line of sight, carrying loads up to 2.5 kg within a 3 km radius. ParaZero's patented SafeAir system enhances drone safety with a real-time monitoring smart parachute. The commercial drone market is anticipated to reach $85 billion by 2025, emphasizing the significance of this development in opening new business opportunities for commercial operators.
Medigus Ltd. (MDGS) has announced a strategic investment in Clearmind Medicine Inc., committing US $1.25 million to acquire approximately 2 million units (5.02% equity). This investment aims to expand Medigus' healthcare involvement, particularly in developing psychedelic-derived therapeutics. The joint venture will focus on food supplements based on Clearmind's intellectual property, alongside the goal of regulatory approvals for product distribution. The psychedelic market is projected to grow to USD $10.75 billion by 2027.
Medigus Ltd. (Nasdaq: MDGS) has acquired approximately 40% of an Israeli drone technology company known for its patented safety system designed to prevent drone crashes. This innovative system features a smart parachute that autonomously deploys during emergencies, addressing safety concerns for commercial drones operating near people and structures. With over 870,000 registered drones in the U.S., this investment taps into a multi-billion-dollar market. The technology complies with FAA regulations and is currently being commercialized globally.
FAQ
What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?
What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?
What does Medigus Ltd. specialize in?
What is the SRS system?
How does the SRS system benefit GERD patients?
Does Medigus Ltd. collaborate with other companies?
Where is Medigus Ltd. based?
Who can I contact for investor relations at Medigus?
What is the primary medical condition that Medigus's technology addresses?
How does the SRS system work?
What are the recent initiatives of Medigus Ltd.?
How can I get the latest news about Medigus Ltd.?
